STOCK TITAN

Waterdrop Inc. Announces Third Quarter 2024 Unaudited Financial Results

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Waterdrop Inc. (NYSE: WDH) reported strong Q3 2024 financial results with significant profitability improvement. Net profit reached RMB92.8 million, up 152.6% year-over-year. First-year premiums (FYP) grew 20.4% to RMB2,041.8 million, while net operating revenue increased 2.6% to RMB704.1 million.

The company's insurance business maintained an operating profit margin above 20%, with 14.8% quarter-over-quarter FYP growth. The medical crowdfunding platform expanded its reach, with 466 million people donating RMB66.3 billion to 3.32 million patients. The digital clinical trial solution showed 17.4% quarter-over-quarter growth, collaborating with 184 pharmaceutical companies and CROs.

By November 2024, Waterdrop had repurchased approximately 50.9 million ADSs and completed a second special cash dividend of US$7.3 million.

Waterdrop Inc. (NYSE: WDH) ha riportato risultati finanziari solidi per il terzo trimestre del 2024 con un significativo miglioramento della redditività. L'utile netto ha raggiunto 92,8 milioni di RMB, in aumento del 152,6% rispetto all'anno precedente. I premi del primo anno (FYP) sono aumentati del 20,4% a 2.041,8 milioni di RMB, mentre il fatturato operativo netto è cresciuto del 2,6% a 704,1 milioni di RMB.

Il business assicurativo dell'azienda ha mantenuto un margine di profitto operativo superiore al 20%, con una crescita FYP del 14,8% rispetto al trimestre precedente. La piattaforma di crowdfunding medicale ha ampliato la sua portata, con 466 milioni di persone che hanno donato 66,3 miliardi di RMB a 3,32 milioni di pazienti. La soluzione per studi clinici digitali ha mostrato una crescita del 17,4% rispetto al trimestre precedente, collaborando con 184 aziende farmaceutiche e CRO.

Entro novembre 2024, Waterdrop aveva riacquistato circa 50,9 milioni di ADS e completato un secondo dividendo in contante speciale di 7,3 milioni di dollari statunitensi.

Waterdrop Inc. (NYSE: WDH) reportó resultados financieros sólidos para el tercer trimestre de 2024 con una mejora significativa en la rentabilidad. La utilidad neta alcanzó 92,8 millones de RMB, un aumento del 152,6% interanual. Las primas de primer año (FYP) crecieron un 20,4% hasta 2.041,8 millones de RMB, mientras que los ingresos operativos netos aumentaron un 2,6% hasta 704,1 millones de RMB.

El negocio de seguros de la compañía mantuvo un margen de utilidad operativa superior al 20%, con un crecimiento FYP del 14,8% respecto al trimestre anterior. La plataforma de crowdfunding médico amplió su alcance, con 466 millones de personas donando 66,3 mil millones de RMB a 3,32 millones de pacientes. La solución de ensayos clínicos digitales mostró un crecimiento del 17,4% respecto al trimestre anterior, colaborando con 184 empresas farmacéuticas y CROs.

Para noviembre de 2024, Waterdrop había recomprado aproximadamente 50,9 millones de ADS y completado un segundo dividendo en efectivo especial de 7,3 millones de dólares estadounidenses.

Waterdrop Inc. (NYSE: WDH)는 2024년 3분기 강력한 재무 실적을 보고하며 수익성이 크게 개선되었다고 발표했습니다. 순이익은 92.8백만 RMB에 도달하여 전년 대비 152.6% 증가했습니다. 첫 해 보험료(FYP)는 2041.8백만 RMB로 20.4% 증가했으며, 순 운영 수익은 704.1백만 RMB로 2.6% 증가했습니다.

회사의 보험 사업은 20% 이상의 운영 이익률을 유지하고 있으며, 전 분기 대비 FYP가 14.8% 증가했습니다. 의료 크라우드펀딩 플랫폼은 4억 6,600만 명이 663억 RMB를 332만 명의 환자에게 기부하면서 범위를 확장했습니다. 디지털 임상 시험 솔루션은 17.4%의 분기 대비 성장을 보여주며 184개의 제약사 및 CRO와 협력하고 있습니다.

2024년 11월까지 Waterdrop은 약 5090만 개의 ADS를 재구매했으며, 730만 달러의 두 번째 특별 현금 배당금을 완료했습니다.

Waterdrop Inc. (NYSE: WDH) a annoncé de solides résultats financiers pour le troisième trimestre 2024, avec une amélioration significative de la rentabilité. Le bénéfice net a atteint 92,8 millions RMB, en hausse de 152,6 % par rapport à l'année précédente. Les primes de première année (FYP) ont augmenté de 20,4 % pour atteindre 2.041,8 millions RMB, tandis que le chiffre d'affaires opérationnel net a augmenté de 2,6 % pour atteindre 704,1 millions RMB.

L'activité d'assurance de l'entreprise a maintenu une marge bénéficiaire opérationnelle supérieure à 20 %, avec une croissance des FYP de 14,8 % par rapport au trimestre précédent. La plateforme de financement participatif médical a élargi son champ d'action, avec 466 millions de personnes ayant fait don de 66,3 milliards de RMB à 3,32 millions de patients. La solution d'essai clinique numérique a montré une croissance de 17,4 % par rapport au trimestre précédent, collaborant avec 184 entreprises pharmaceutiques et CRO.

En novembre 2024, Waterdrop avait racheté environ 50,9 millions d'ADS et avait effectué un deuxième dividende en espèces spécial de 7,3 millions de dollars américains.

Waterdrop Inc. (NYSE: WDH) hat für das dritte Quartal 2024 starke Finanzzahlen veröffentlicht, mit einer deutlichen Verbesserung der Rentabilität. Der Nettogewinn erreichte 92,8 Millionen RMB, was einem Anstieg von 152,6 % im Vergleich zum Vorjahr entspricht. Die Erstanlageprämien (FYP) stiegen um 20,4 % auf 2.041,8 Millionen RMB, während der Nettobetriebsumsatz um 2,6 % auf 704,1 Millionen RMB zunahm.

Das Versicherungsgeschäft des Unternehmens hielt die operative Gewinnmarge über 20 %, mit einem FYP-Wachstum von 14,8 % im Quartalsvergleich. Die medizinische Crowdfunding-Plattform erweiterte ihre Reichweite, wobei 466 Millionen Menschen 66,3 Milliarden RMB an 3,32 Millionen Patienten spendeten. Die digitale klinische Studienlösung zeigte ein Wachstum von 17,4 % im Quartalsvergleich und kooperierte mit 184 Pharmaunternehmen und CROs.

Bis November 2024 hatte Waterdrop etwa 50,9 Millionen ADS zurückgekauft und eine zweite Sonderdividende von 7,3 Millionen US-Dollar ausgeschüttet.

Positive
  • Net profit grew 152.6% YoY to RMB92.8 million
  • FYP increased 20.4% YoY to RMB2,041.8 million
  • Insurance business maintained >20% operating profit margin
  • Operating revenue grew 2.6% YoY to RMB704.1 million
  • Digital clinical trial solution revenue increased 17.4% QoQ
  • Positive operating cash flow maintained in Q3 2024
Negative
  • Insurance-related income decreased 3.0% YoY to RMB600.7 million
  • Digital clinical trial solution income declined 12.1% YoY
  • Crowdfunding service fees decreased 5.0% QoQ

Insights

Waterdrop delivered strong Q3 2024 results with significant profitability improvement. Net profit surged 152.6% year-over-year to RMB92.8 million, while first-year premiums grew 20.4% to RMB2.04 billion. The insurance segment maintained healthy 20%+ operating margins despite market challenges.

Key positives include robust premium growth in both short and long-term insurance products, 17.4% quarter-over-quarter growth in digital clinical trials and successful AI initiatives generating meaningful premium contributions. The company continues to demonstrate strong cash generation with RMB3.44 billion in cash position and has returned value to shareholders through share buybacks and dividends.

The company's AI initiatives show promising commercial traction. The 'AI Consultant' powered by their proprietary large language model is already generating millions in monthly premiums. The launch of 'AI Top Sales Platform 3.0' for customizing AI sales agents and the deployment of 'AI Service Quality Agent' demonstrate meaningful progress in AI monetization and operational efficiency improvements.

The digital transformation efforts across insurance distribution and clinical trial patient recruitment showcase Waterdrop's successful pivot toward technology-driven solutions. With 909 patients enrolled and 88 new programs initiated in Q3, the platform is gaining momentum in the digital clinical trials space.

BEIJING, Dec. 11, 2024 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three and nine months ended September 30, 2024.

Financial and Operational Highlights for the Third Quarter of 2024

  • Marked improvement in profitability and healthy liquidity: In the third quarter of 2024, net profit attributable to our ordinary shareholders reached RMB92.8 million, representing a year-over-year growth of 152.6%. As of September 30, 2024, we continued to generate positive operating cash flow during the third quarter of 2024.
  • Strong business performance: For the third quarter of 2024, the first-year premiums ("FYP") generated through our insurance business amounted to RMB2,041.8 million (US$290.9 million), representing an increase of 20.4% year over year. Net operating revenue was RMB704.1 million (US$100.3 million), representing an increase of 2.6% year over year.
  • Expanded crowdfunding coverage: As of September 30, 2024, around 466 million people cumulatively had donated an aggregate of RMB66.3 billion to 3.32 million patients through Waterdrop Medical Crowdfunding.
  • Dependable performance in patient recruitment: As of September 30, 2024, the Company had cumulatively enrolled over 9,500 patients into 1,137 clinical trial programs through the E-Find Platform.

Mr. Peng Shen, Founder, Chairman, and Chief Executive Officer of Waterdrop, commented, "We are delighted to announce another quarter of robust profitability, with net profit attributable to ordinary shareholders reaching 2.5 times that of the third quarter last year.

Our insurance business has achieved a 14.8% quarter-over-quarter growth in FYP and maintained an operating profit margin above 20%. We delivered solid FYP growth in both short-term and long-term insurance, driven by user acquisition, innovative tailor-made products, and the contribution of Shenlanbao. I believe with our data-driven user insights, unique product offerings, and diversified distribution channels, we are well-positioned to maintain a strong competitive advantage.

This quarter marks a significant milestone for our medical crowdfunding business and the industry as a whole, following the issuance of the 'Measures for Administration of Online Service Platforms for Individuals Seeking Financial Help' released by Ministry of Civil Affairs of PRC and other government departments on September 5, 2024. The Measures for Administration officially announce the legal framework of fundraising sector, and offer guidance on management and information transparency.

During this quarter, our digital clinical trial solution income continued its growth, realizing a quarter-over-quarter increase of 17.4%. We collaborated with a total of 184 pharmaceutical companies and contract research organizations ("CROs"). Moreover, we enrolled 909 patients and initiated services for 88 new programs during the third quarter of 2024.

We are also delighted to report notable progress in AI. Internally, 'AI Consultant', a conversational AI agent powered by our 'Waterdrop Guardian' large language model, has reached the capacity to generate million yuan in monthly premiums by serving user inquires. Meanwhile, a new application, 'AI Service Quality Agent', was deployed to streamline the service quality inspection process by replacing manual work. Externally, we launched 'AI Top Sales Platform 3.0', a conversational AI platform that customizes AI sales agents for businesses, and have initiated pilots with insurance carriers and companies in non-insurance sectors.

We value the trust from our investors and prioritize shareholder returns. By the end of November 2024, the Company had cumulatively repurchased approximately 50.9 million ADSs from the open market. Moreover, we recently completed our second special cash dividend of approximately US$7.3 million.

With our strong execution capability, ample cash reserves and continuous profitability, we will continue to focus on fostering sustainable growth, and strive to deliver substantial returns to our shareholders and investors."

Financial Results for the Third Quarter of 2024

Operating revenue, net

Net operating revenue for the third quarter of 2024 increased by 2.6% year over year to RMB704.1 million (US$100.3 million) from RMB686.5 million for the same period of 2023. On a quarter-over-quarter basis, net operating revenue increased by 4.1%.

  • Insurance-related income includes insurance brokerage income and technical service income. Insurance brokerage income represents brokerage commissions earned from insurance companies. Technical service income is derived from providing technical services including customer relationship maintenance, customer complaint management, claim review, and user referral services, among other things, to insurance companies, insurance brokers, and agency companies. Our insurance-related income amounted to RMB600.7 million (US$85.6 million) in the third quarter of 2024, representing a decrease of 3.0% year over year from RMB619.3 million for the third quarter of 2023, which was mainly due to the decrease in technical service income. On a quarter-over-quarter basis, insurance-related income increased by 4.7%.
  • Crowdfunding service fees represent the service income earned when patients successfully withdraw the proceeds from their crowdfunding campaigns. Our role is to operate the Waterdrop Medical Crowdfunding platform to provide crowdfunding related services through the internet, enabling patients with significant medical bills to seek help from caring hearts through technology (the "medical crowdfunding services"). Our medical crowdfunding services generally consist of providing technical and internet support, managing, reviewing and supervising the crowdfunding campaigns, providing comprehensive risk management and anti-fraud measures, and facilitating the collection and transfer of the funds. For the third quarter of 2024, we generated RMB65.8 million (US$9.4 million) in service fees, representing an increase of 83.0% year over year from RMB36.0 million for the third quarter of 2023. On a quarter-over-quarter basis, crowdfunding service fees decreased by 5.0%.
  • Digital clinical trial solution income represents the service income earned from our customers mainly including biopharmaceutical companies and leading biotechnology companies. We match qualified and suitable patients for enrollment in clinical trials for our customers and generate digital clinical trial solution revenue for successful matches and we typically charge our customers a fixed unit price per successful match. For the third quarter of 2024, our digital clinical trial solution income amounted to RMB24.3 million (US$3.5 million), representing a decrease of 12.1% from RMB27.6 million in the same period of 2023. On a quarter-over-quarter basis, digital clinical trial solution income increased by 17.4%.

Operating costs and expenses

Operating costs and expenses decreased by 1.6% year over year to RMB677.7 million (US$96.6 million) for the third quarter of 2024. On a quarter-over-quarter basis, operating costs and expenses increased by 8.6%.

  • Operating costs increased by 9.1% year over year to RMB340.6 million (US$48.5 million) for the third quarter of 2024, as compared with RMB312.3 million for the third quarter of 2023, which was primarily driven by (i) an increase of RMB46.5 million in costs of referral and service fees, partially offset by (ii) a decrease of RMB10.0 million in personnel costs, and (iii) a decrease of RMB7.0 million in the costs for crowdfunding consultants team. On a quarter-over-quarter basis, operating costs increased by 6.7% from RMB319.1 million, primarily due to (i) an increase of RMB32.6 million in costs of referral and service fees, partially offset by (ii) a decrease of RMB8.9 million in personnel costs, and (iii) a decrease of RMB5.1 million in the costs for crowdfunding consultants team.
  • Sales and marketing expenses decreased by 7.7% year over year to RMB173.2 million (US$24.7 million) for the third quarter of 2024, as compared with RMB187.7 million for the same quarter of 2023. The decrease was primarily due to (i) a decrease of RMB36.5 million in personnel costs and share-based compensation expenses, partially offset by (ii) an increase of RMB21.1 million in marketing expenses to third-party traffic channels. On a quarter-over-quarter basis, sales and marketing expenses increased by 10.0% from RMB157.4 million, primarily due to (i) an increase of RMB14.4 million in marketing expenses to third-party traffic channels, (ii) an increase of RMB4.5 million in outsourced sales and marketing service fees to third parties, and partially offset by (iii) a decrease of RMB3.1 million in sales and marketing personnel costs and share-based compensation expenses
  • General and administrative expenses decreased by 3.2% year over year to RMB111.0 million (US$15.8 million) for the third quarter of 2024, compared with RMB114.6 million for the same quarter of 2023. The year-over-year variance was due to (i) a decrease of RMB24.8 million in professional service fees, (ii) a decrease of RMB5.8 million in personnel costs and share-based compensation expenses, partially offset by (iii) an increase of RMB10.6 million in allowance for doubtful accounts, and (iv) an increase of RMB20.6 million impairment loss for intangible assets related to the acquisition of Shenzhen Cunzhen Qiushi Technology Co., Ltd. and its subsidiaries ("Shenlanbao"). On a quarter-over-quarter basis, general and administrative expenses increased by 18.1% from RMB94.0 million, due to (i) an increase of RMB20.6 million impairment loss for intangible assets related to the acquisition of Shenlanbao, (ii) an increase of RMB6.9 million in personnel costs and share-based compensation expenses, partially offset by (iii) a decrease of RMB6.8 million in professional service fees, and (iv) a decrease of RMB3.1 million allowance for doubtful accounts.
  • Research and development expenses decreased by 28.4% year over year to RMB53.0 million (US$7.5 million) for the third quarter of 2024, compared with RMB73.9 million for the same period of 2023. The decrease was primarily due to a decrease of RMB18.9 million in personnel costs and share-based compensation expenses. On a quarter-over-quarter basis, research and development expenses remained stable.

Operating profit for the third quarter of 2024 was RMB26.5 million (US$3.8 million), as compared with an operating loss of RMB2.1 million for the third quarter of 2023 and an operating profit of RMB52.4 million for the second quarter of 2024.

Interest income for the third quarter of 2024 was RMB36.0 million (US$5.1 million), as compared with RMB32.9 million for the third quarter of 2023 and RMB37.5 million for the second quarter of 2024.

Income tax benefit for the third quarter of 2024 was RMB7.8 million (US$1.1 million), as compared with RMB1.5 million for the third quarter of 2023 and an income tax expense of RMB7.0 million for the second quarter of 2024.

Net profit attributable to the Company's ordinary shareholders for the third quarter of 2024 was RMB92.8 million (US$13.2 million), as compared with RMB36.7 million for the same period of 2023, and RMB88.3 million for the second quarter of 2024.

Adjusted net profit attributable to the Company's ordinary shareholders (non-GAAP(1)) for the third quarter of 2024 was RMB126.0 million (US$18.0 million), as compared with RMB74.3 million for the same period of 2023, and RMB108.7 million for the second quarter of 2024. 

Cash position(2)

As of September 30, 2024, cash position of the Company was RMB3,440.1 million (US$490.2 million), as compared with RMB3,571.6 million as of December 31, 2023.


(1) See the sections entitled "Non-GAAP Financial Measure" and "Reconciliations of GAAP and Non-GAAP Results" for more information about the non-GAAP
     measures referred to in this announcement.
(2) Cash position includes cash and cash equivalents, short-term investments, and long-term debt investments included in long-term investments.

Share Repurchase Programs 

Pursuant to the share repurchase programs launched in September 2021, September 2022, September 2023 and September 2024, respectively, we had cumulatively repurchased approximately 50.9 million ADSs from the open market with cash for a total consideration of approximately US$102.3 million as of November 30, 2024.

Supplemental Information 

We organize and report our business in three operating segments:

  • Insurance, which mainly includes Waterdrop Insurance Marketplace, Shenlanbao Insurance Marketplace and technical support service;
  • Crowdfunding, which mainly includes Waterdrop Medical Crowdfunding; and
  • Others, which mainly include Digital Clinical Trial Solution and other new initiatives.

The table below sets forth the segment operating results, with the nine-month comparative figures retrospectively adjusted to conform to this presentation.



For the Three Months Ended 


For the Nine Months Ended 



September 30,
2023


June 30,
2024


September 30,
2024


September
30, 2023*


September 30,
2024



RMB


RMB


RMB


USD


RMB


RMB


USD



(All amounts in thousands)






Operating revenue, net















 Insurance 


619,269


573,832


600,726


85,603


1,753,049


1,781,335


253,838

 Crowdfunding 


35,971


69,323


65,839


9,382


122,670


202,512


28,858

 Others 


31,238


33,001


37,576


5,354


95,624


101,150


14,414

Total consolidated operating
   revenue, net


686,478


676,156


704,141


100,339


1,971,343


2,084,997


297,110

Operating profit/(loss)















 Insurance 


145,200


122,955


122,501


17,457


399,914


374,619


53,383

 Crowdfunding 


(68,793)


(22,936)


(17,902)


(2,551)


(194,058)


(73,075)


(10,413)

 Others 


(43,713)


(27,450)


(31,716)


(4,520)


(128,157)


(90,598)


(12,911)

Total segment operating
   profit


32,694


72,569


72,883


10,386


77,699


210,946


30,059

 Unallocated item** 


(34,762)


(20,205)


(46,413)


(6,614)


(111,081)


(85,748)


(12,219)

Total consolidated operating
   (loss)/profit


(2,068)


52,364


26,470


3,772


(33,382)


125,198


17,840

 Total other income 


36,914


38,366


60,842


8,670


126,520


141,989


20,233

Profit before income tax


34,846


90,730


87,312


12,442


93,138


267,187


38,073

 Income tax benefit/(expense) 


1,479


(7,026)


7,843


1,118


14,609


(7,771)


(1,107)

Net profit


36,325


83,704


95,155


13,560


107,747


259,416


36,966
















*       Starting from the second quarter of 2023, our chief operating decision maker began managing the business through three
        operating segments and assessing performance and allocating resources under this new operating segment structure. The
        nine-month comparative figures were retrospectively adjusted to conform to this presentation.

**     The share-based compensation and impairment of intangible assets acquired from business combination represent
        unallocated items in the segment information because our management does not consider these as part of the segment
        operating performance measure.

Exchange Rate

This announcement contains translations of certain RMB amounts into U.S. dollars ("USD" or "US$") at specified rates solely for the convenience of the reader. Unless otherwise stated, all translations from RMB to USD were made at the rate of RMB7.0176 to US$1.00, the noon buying rate in effect on September 30, 2024 in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or USD amounts referred could be converted into USD or RMB, as the case may be, at any particular rate or at all. For analytical presentation, all percentages are calculated using the numbers presented in the financial statements contained in this earnings release.

Non-GAAP Financial Measure

The Company uses non-GAAP financial measure, adjusted net profit attributable to our ordinary shareholders, in evaluating the Company's operating results and for financial and operational decision-making purposes. Adjusted net profit attributable to our ordinary shareholders represents net profit attributable to our ordinary shareholders excluding share-based compensation expense attributable to our ordinary shareholders, foreign currency exchange gain or losses, impairment of intangible assets acquired from business combination and related tax effects on non-GAAP adjustments

The non-GAAP financial measure is not presented in accordance with U.S. GAAP and may be different from non-GAAP methods of accounting and reporting used by other companies. The non-GAAP financial measure has limitations as analytical tools and when assessing the Company's operating performance, investors should not consider it in isolation, or as a substitute for net loss or other consolidated statements of comprehensive loss data prepared in accordance with U.S. GAAP. The Company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure. Investors are encouraged to review the Company's historical non-GAAP financial measure to the most directly comparable GAAP measure. Adjusted net profit attributable to our ordinary shareholders presented here may not be comparable to similarly titled measure presented by other companies. Other companies may calculate similarly titled measure differently, limiting its usefulness as a comparative measure to our data.

The Company mitigates these limitations by reconciling the non-GAAP financial measure to the most comparable U.S. GAAP performance measure, all of which should be considered when evaluating the Company's performance.

For more information on the non-GAAP financial measure, please see the table captioned "Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.

Safe Harbor Statement

This press release contains statements that may constitute "forward-looking" statements pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "future," "intends," "plans," "believes," "estimates," "likely to" and similar statements. Among other things, quotations in this announcement, contain forward-looking statements. Waterdrop may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Waterdrop's beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Waterdrop's mission, goals and strategies; Waterdrop's future business development, financial condition and results of operations; the expected growth of the insurance, medical crowdfunding and healthcare industry in China; Waterdrop's expectations regarding demand for and market acceptance of our products and services; Waterdrop's expectations regarding its relationships with consumers, insurance carriers and other partners; competition in the industry and relevant government policies and regulations relating to insurance, medical crowdfunding and healthcare industry. Further information regarding these and other risks is included in Waterdrop's filings with the SEC. All information provided in this press release is as of the date of this press release, and Waterdrop does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Conference Call Information

Waterdrop's management team will hold a conference call on December 11, 2024 at 7:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong Time on the same day) to discuss the financial results. Dial-in details for the earnings conference call are as follows:

International:

1-412-317-6061

United States Toll Free:

1-888-317-6003

Hong Kong Toll Free:

800-963976

Hong Kong:

852-58081995

Mainland China:

4001-206115

Chinese Line (Mandarin) Entry Number:

4533234

English Interpretation Line (Listen-only Mode) Entry Number:

2061532

Participants can choose between the Chinese and the English interpretation lines. Please note that the English interpretation option will be in listen-only mode. Please dial in 15 minutes before the call is scheduled to begin and provide the Elite Entry Number to join the call.

Telephone replays will be accessible two hours after the conclusion of the conference call until December 18, 2024 by dialing the following numbers:

United States Toll Free:

1-877-344-7529

International:

1-412-317-0088

Chinese Line Access Code:

6305770

English Interpretation Line Access Code:

9765426

A live and archived webcast of the conference call will also be available at the Company's investor relations website at http://ir.waterdrop-inc.com/.

About Waterdrop Inc.

Waterdrop Inc. (NYSE: WDH) is a leading technology platform dedicated to insurance and healthcare service with a positive social impact. Founded in 2016, with the comprehensive coverage of Waterdrop Insurance Marketplace and Waterdrop Medical Crowdfunding, Waterdrop aims to bring insurance and healthcare service to billions through technology. For more information, please visit www.waterdrop-inc.com.

For investor inquiries, please contact

Waterdrop Inc.
IR@shuidi-inc.com 

WATERDROP INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(All amounts in thousands, unless otherwise noted)


As of 


December 31, 2023


September 30, 2024


RMB


RMB


USD

Assets






Current assets






       Cash and cash equivalents

396,905


442,145


63,005

       Restricted cash 

577,121


474,683


67,642

       Short-term investments

2,996,527


1,912,873


272,582

       Accounts receivable, net 

693,110


755,427


107,647

       Current contract assets 

572,871


631,507


89,989

       Amount due from related parties

65


250


36

       Prepaid expense and other assets

189,846


192,153


27,381

Total current assets

5,426,445


4,409,038


628,282

Non-current assets






       Non-current contract assets

134,383


141,262


20,130

       Property, equipment and software, net

33,878


237,616


33,860

       Intangible assets, net

177,407


153,043


21,808

       Long-term investments

211,758


1,122,407


159,942

       Right of use assets, net

59,851


55,149


7,859

       Deferred tax assets

24,190


29,297


4,175

       Goodwill

80,751


80,751


11,507

Total non-current assets

722,218


1,819,525


259,281

Total assets

6,148,663


6,228,563


887,563







Liabilities, Mezzanine Equity and Shareholders' Equity 






Current liabilities






       Amount due to related parties

9,509


10,043


1,431

       Insurance premium payables 

591,953


493,596


70,337

       Accrued expenses and other current liabilities

597,684


724,610


103,256

       Short-term loans

137,557


148,544


21,167

       Current lease liabilities

32,908


35,946


5,122

Total current liabilities 

1,369,611


1,412,739


201,313

Non-current liabilities






       Non-current lease liabilities

27,293


18,464


2,631

       Deferred tax liabilities

73,305


85,713


12,214

Total non-current liabilities

100,598


104,177


14,845

Total liabilities

1,470,209


1,516,916


216,158







Mezzanine Equity






       Redeemable non-controlling interests

92,760


90,449


12,889







Shareholders' equity






       Class A ordinary shares

112


113


16

       Class B ordinary shares

27


27


4

       Treasury stock

(12)


(15)


(2)

       Additional paid-in capital

7,003,423


6,821,616


972,073

       Accumulated other comprehensive income

144,107


99,693


14,206

       Accumulated deficit

(2,561,963)


(2,300,236)


(327,781)

Total shareholders' equity

4,585,694


4,621,198


658,516

Total liabilities, mezzanine equity and shareholders' equity

6,148,663


6,228,563


887,563

 

 

 

WATERDROP INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(All amounts in thousands, except for share and per share data, or otherwise noted)




For the Three Months Ended 


For the Nine Months Ended 



September 30, 2023


June 30, 2024


September 30, 2024


September 30, 2023


September 30, 2024



RMB


RMB


RMB


USD


RMB


RMB


USD
















Operating revenue, net


686,478


676,156


704,141


100,339


1,971,343


2,084,997


297,110

Operating costs and expenses(i)















 Operating costs 


(312,278)


(319,101)


(340,560)


(48,529)


(893,401)


(990,904)


(141,203)

 Sales and marketing expenses 


(187,685)


(157,413)


(173,172)


(24,677)


(565,634)


(512,731)


(73,064)

 General and administrative expenses 


(114,641)


(93,978)


(110,988)


(15,816)


(306,436)


(293,927)


(41,884)

 Research and development expenses 


(73,942)


(53,300)


(52,951)


(7,545)


(239,254)


(162,237)


(23,119)

Total operating costs and expenses


(688,546)


(623,792)


(677,671)


(96,567)


(2,004,725)


(1,959,799)


(279,270)

Operating (loss)/profit


(2,068)


52,364


26,470


3,772


(33,382)


125,198


17,840

Other income















 Interest income 


32,890


37,510


36,005


5,131


101,384


113,319


16,148

 Foreign currency exchange (loss)/gain 


(3,734)


(444)


7,909


1,127


(2,614)


8,979


1,279

 Others, net 


7,758


1,300


16,928


2,412


27,750


19,691


2,806

Profit before income tax


34,846


90,730


87,312


12,442


93,138


267,187


38,073

 Income tax benefit/(expense) 


1,479


(7,026)


7,843


1,118


14,609


(7,771)


(1,107)

Net profit 


36,325


83,704


95,155


13,560


107,747


259,416


36,966

 Net (loss)/profit attributable to mezzanine
   equity classified as non-controlling interests
   shareholders 


(417)


(4,586)


2,350


335


(417)


(2,311)


(329)

Net profit attributable to ordinary shareholders


36,742


88,290


92,805


13,225


108,164


261,727


37,295

Other comprehensive income:















 Foreign currency translation adjustment, net of
   tax 


8,983


13,497


(83,054)


(11,835)


76,803


(44,414)


(6,329)

 Unrealized loss on available for sale
   investments, net of tax 


-


-


-


-


(1,551)


-


-

Total comprehensive income


45,308


97,201


12,101


1,725


182,999


215,002


30,637

 Total comprehensive (loss)/profit attributable
   to mezzanine equity classified as non-
   controlling interests shareholders 


(417)


(4,586)


2,350


335


7,074


(2,311)


(329)

Total comprehensive income attributable to
   ordinary shareholders


45,725


101,787


9,751


1,390


175,925


217,313


30,966

Weighted average number of ordinary shares
   used in computing net profit per share















 Basic 


3,719,628,339


3,660,589,600


3,624,431,887


3,624,431,887


3,793,678,209


3,660,415,080


3,660,415,080

 Diluted 


3,808,529,672


3,734,346,444


3,689,357,838


3,689,357,838


3,921,118,226


3,726,590,324


3,726,590,324

Net profit per share attributable to ordinary shareholders















 Basic 


0.01


0.02


0.03


0.00


0.03


0.07


0.01

 Diluted 


0.01


0.02


0.03


0.00


0.03


0.07


0.01































(i)  Share-based compensation expenses are included in the operating costs and expenses as follows. 




























For the Three Months Ended 


For the Nine Months Ended 



September 30, 2023


June 30, 2024


September 30, 2024


September 30, 2023


September 30, 2024



RMB


RMB


RMB


USD


RMB


RMB


USD

Sales and marketing expenses


(8,944)


(1,320)


(1,993)


(284)


(33,361)


(5,133)


(731)

General and administrative expenses


(22,060)


(16,285)


(21,297)


(3,035)


(66,642)


(51,909)


(7,397)

Research and development expenses


(3,758)


(2,600)


(2,563)


(365)


(11,078)


(8,146)


(1,161)

Total 


(34,762)


(20,205)


(25,853)


(3,684)


(111,081)


(65,188)


(9,289)

 

WATERDROP INC.

RECONCILIATIONS OF GAAP AND NON-GAAP RESULTS

(All amounts in thousands, unless otherwise noted)

































For the Three Months Ended 


For the Nine Months Ended 



September 30, 2023


June 30, 2024


September 30, 2024


September 30, 2023


September 30, 2024



RMB


RMB


RMB


USD


RMB


RMB


USD
















Net profit attributable to the Company's ordinary
  shareholders


36,742


88,290


92,805


13,225


108,164


261,727


37,295

Add:















 Share-based compensation expense attributable to
the Company's ordinary shareholders 


33,810


20,015


25,673


3,658


110,130


64,948


9,255

 Foreign currency exchange loss/(gain) 


3,734


444


(7,909)


(1,127)


2,614


(8,979)


(1,279)

 Impairment of intangible assets acquired from
business combination 


-


-


20,560


2,930


-


20,560


2,930

 Tax effects on non-GAAP adjustments 


-


-


(5,140)


(732)


-


(5,140)


(732)

Adjusted net profit attributable to the Company's
ordinary shareholders


74,286


108,749


125,989


17,954


220,908


333,116


47,469

 

 

 

Cision View original content:https://www.prnewswire.com/news-releases/waterdrop-inc-announces-third-quarter-2024-unaudited-financial-results-302328817.html

SOURCE Waterdrop Inc.

FAQ

What was Waterdrop's (WDH) net profit in Q3 2024?

Waterdrop's net profit in Q3 2024 was RMB92.8 million (US$13.2 million), representing a 152.6% increase year-over-year.

How much did WDH's First-Year Premiums (FYP) grow in Q3 2024?

WDH's FYP grew 20.4% year-over-year to RMB2,041.8 million (US$290.9 million) in Q3 2024.

What was WDH's operating revenue in Q3 2024?

WDH's net operating revenue in Q3 2024 was RMB704.1 million (US$100.3 million), a 2.6% increase year-over-year.

How many ADSs has WDH repurchased as of November 2024?

As of November 2024, WDH had repurchased approximately 50.9 million ADSs from the open market for a total consideration of approximately US$102.3 million.

What was WDH's cash position as of September 30, 2024?

WDH's cash position was RMB3,440.1 million (US$490.2 million) as of September 30, 2024.

Waterdrop Inc. American Depositary Shares (each representing the right to receive 10

NYSE:WDH

WDH Rankings

WDH Latest News

WDH Stock Data

442.73M
282.60M
0.87%
2.87%
0.1%
Insurance - Diversified
Financial Services
Link
United States of America
Beijing